Jan-Olav Henck, PhD,
chief scientific officer
Jan-Olav Henck, PhD, chief scientific officer at Aptuit, discusses strategies and considerations in polymorph screening with Patricia Van Arnum, senior editor of Pharmaceutical Technology (Posted November 2011).
Better equipment and automated processes will be key. So, too, will the right way of approaching outsourcing relationships.
Data sharing and a common data model can improve CRO partnerships and trial results.
As CMOs shed their old toll processing role, sponsors can expect the right questions, proactive communication, and a firm grasp of risk management and tech transfer from contract service providers.
FDA announced that it would postpone a meeting that would be critical for the advancement of Celltrion’s Remicade biosimilar in the US.
FDA approved Actavis’ antibiotic Avycaz designed to combat drug-resistant bacteria.
Johnson & Johnson will pay $2.5 million to a plaintiff who developed gynecomastia after using Risperdal.
Ingredients InsiderCynthia ChallenerFDA Approves Novel Treatments in 2014